In recent years, the biotech financing landscape has been in a period of tumult, with ever-growing competition and shifts in the global policy landscape contributing to a challenging fundraising environment.
While various hurdles remain, biotechs must still find a way to attract investor attention to secure capital to fund their drug development efforts and build up their all-crucial data packages.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In this episode of the GlobalData Healthcare Podcast, recorded at the 2026 Outsourcing in Clinical Trials and Clinical Trial Supply Nordics conference, held in Copenhagen, Denmark, Clinical Trials Arena reporter, Annabel Kartal-Allen, chats with Stephan Christgau, founding partner at Eir Ventures.
He discusses what looks for in a biotech when making investment decisions, and what is catching his eye as an investor in a sea of innovation.
Christgau also elaborates on the importance of developing an effective clinical strategy to garner the trust of a prospective investor – diving into what separates a good data package from a great one, and what he looks for in this realm when allocating capital.
If you liked this episode of the GlobalData Healthcare podcast, you can find a range of episodes, which bring you key insights into the world of pharma, biotech, medical devices and clinical trials, at this link.
